Captopril and Hypertension

I Humoral and Physiological Mechanisms in Hypertension.- 1Blood Pressure Homeostasis.- 2Mechanisms of Hypertension Induced by Electrolyte-Active Steroids.- 3The Relationship of the Renal Medulla to the Hypertensive State.- 4The Influence of Various Neurological Defects on the Release of Renin in Normal Man.- 5Angiotensin as a Determinant of Renal Perfusion and Function.- 6Systemic Vascular Resistance: Regulation and Effect on Left Ventricular Function.- II Angiotensin-Converting Enzyme: Its Role and Development of Inhibitors.- 7Physiological, Biochemical, and Immunologic Aspects of Angiotensin-Converting Enzyme.- 8Design of New Antihypertensive Drugs: Potent and Specific Inhibitors of Angiotensin-Converting Enzyme.- 9Captopril (Capoten®; SQ 14,225) (D-3-Mercapto-2-methylpropanoyl-L-proline): A Novel Orally Active Inhibitor of Angiotensin-Converting Enzyme and Antihypertensive Agent.- 10Toxicologic and Drug Metabolic Studies of SQ 14,225 in Animals.- 11Captopril: An Oral Angiotensin-Converting Enzyme Inhibitor Active in Man.- III Clinical Use of Converting Enzyme Inhibitors.- 12The Renin System in High Blood Pressure, from Disbelief to Reality: Converting Enzyme Blockade for Analysis and Treatment.- 13Experiences with Blockade of the Renin System in Human Hypertension Using Converting Enzyme Inhibitor SQ 20,881 and Saralasin.- 14The Use of SQ 20,881 Converting Enzyme Inhibitor (Teprotide) for Diagnostic Purposes in Hypertension.- 15Clinical Experience with Blockade of the Renin-Angiotensin-Aldosterone System by an Oral Converting Enzyme Inhibitor (SQ 14,225, Captopril) in Hypertensive Patients.

David Case wurde 1937 in New York geboren und lebte mehrere Jahre in London, Spanien sowie Griechenland.